Does the media refer more to NTLA or ARCT?

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 4 mentions for Intellia Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.53 beat Intellia Therapeutics' score of 0.24 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcturus Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TSHA or ARCT?

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat Arcturus Therapeutics' score of 0.53 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SNDX or ARCT?

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 4 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Arcturus Therapeutics' score of 0.53 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARCT or INBX?

In the previous week, Inhibrx Biosciences had 3 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 9 mentions for Inhibrx Biosciences and 6 mentions for Arcturus Therapeutics. Inhibrx Biosciences' average media sentiment score of 1.05 beat Arcturus Therapeutics' score of 0.53 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arcturus Therapeutics (ARCT) Competitors

$16.03 -0.90 (-5.32%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$16.03 0.00 (0.00%)

As of 09/18/2026 07:33 PM Eastern

Compare

ARCT vs. NTLA, TSHA, FBRX, SNDX, and INBX

Should you buy Arcturus Therapeutics stock or one of its competitors? Arcturus Therapeutics's main competitors and comparable companies include Intellia Therapeutics (NTLA), Taysha Gene Therapies (TSHA), Forte Biosciences (FBRX), Syndax Pharmaceuticals (SNDX), and Inhibrx Biosciences (INBX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arcturus Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Arcturus Therapeutics has a net margin of -317.62% compared to Intellia Therapeutics' net margin of -672.16%. Arcturus Therapeutics' return on equity of -46.54% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 4 mentions for Intellia Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.53 beat Intellia Therapeutics' score of 0.24 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcturus Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Intellia Therapeutics presently has a consensus price target of $20.98, suggesting a potential upside of 72.80%. Arcturus Therapeutics has a consensus price target of $23.00, suggesting a potential upside of 43.48%. Given Intellia Therapeutics' higher probable upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

Arcturus Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	25.14	-$412.69M	-$3.36	N/A
Arcturus Therapeutics	$18.72M	24.33	-$65.78M	-$3.31	N/A

Intellia Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market.

Summary

Arcturus Therapeutics beats Intellia Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Taysha Gene Therapies has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat Arcturus Therapeutics' score of 0.53 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcturus Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies presently has a consensus target price of $12.77, indicating a potential upside of 154.37%. Arcturus Therapeutics has a consensus target price of $23.00, indicating a potential upside of 43.48%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

Arcturus Therapeutics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	167.42	-$109M	-$0.42	N/A
Arcturus Therapeutics	$18.72M	24.33	-$65.78M	-$3.31	N/A

Taysha Gene Therapies has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.48, meaning that its stock price is 148% more volatile than the broader market.

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Arcturus Therapeutics beats Taysha Gene Therapies on 9 of the 17 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Forte Biosciences?

Arcturus Therapeutics (NASDAQ:ARCT) and Forte Biosciences (NASDAQ:FBRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, Arcturus Therapeutics had 6 more articles in the media than Forte Biosciences. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 0 mentions for Forte Biosciences. Arcturus Therapeutics' average media sentiment score of 0.53 beat Forte Biosciences' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Arcturus Therapeutics	Positive
Forte Biosciences	Neutral

Arcturus Therapeutics currently has a consensus price target of $23.00, suggesting a potential upside of 43.48%. Forte Biosciences has a consensus price target of $71.67, suggesting a potential downside of 6.91%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Arcturus Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arcturus Therapeutics has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$18.72M	24.33	-$65.78M	-$3.31	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A

Forte Biosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
Forte Biosciences	N/A	-94.82%	-77.68%

Arcturus Therapeutics has a beta of 2.48, suggesting that its stock price is 148% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.62, suggesting that its stock price is 162% more volatile than the broader market.

Summary

Arcturus Therapeutics beats Forte Biosciences on 14 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 4 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Arcturus Therapeutics' score of 0.53 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcturus Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.5% of Arcturus Therapeutics shares are held by institutional investors. 4.8% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Syndax Pharmaceuticals has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market.

Arcturus Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.06	-$285.42M	-$2.51	N/A
Arcturus Therapeutics	$18.72M	24.33	-$65.78M	-$3.31	N/A

Syndax Pharmaceuticals has a net margin of -87.52% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

Syndax Pharmaceuticals currently has a consensus target price of $42.30, suggesting a potential upside of 140.07%. Arcturus Therapeutics has a consensus target price of $23.00, suggesting a potential upside of 43.48%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Syndax Pharmaceuticals is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Arcturus Therapeutics beats Syndax Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Inhibrx Biosciences?

Arcturus Therapeutics (NASDAQ:ARCT) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

In the previous week, Inhibrx Biosciences had 3 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 9 mentions for Inhibrx Biosciences and 6 mentions for Arcturus Therapeutics. Inhibrx Biosciences' average media sentiment score of 1.05 beat Arcturus Therapeutics' score of 0.53 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcturus Therapeutics has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.66, indicating that its share price is 266% more volatile than the broader market.

Arcturus Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$18.72M	24.33	-$65.78M	-$3.31	N/A
Inhibrx Biosciences	$1.30M	1,238.18	-$140.05M	-$8.88	N/A

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arcturus Therapeutics currently has a consensus target price of $23.00, indicating a potential upside of 43.48%. Inhibrx Biosciences has a consensus target price of $197.50, indicating a potential upside of 80.61%. Given Inhibrx Biosciences' higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Inhibrx Biosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Summary

Arcturus Therapeutics beats Inhibrx Biosciences on 9 of the 16 factors compared between the two stocks.

Get Arcturus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARCT vs. The Competition

Export

Metric	Arcturus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$481.20M	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-4.84	14.08	273.81	25.39
Price / Sales	24.33	1,407.75	692.78	109.00
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	2.13	15.45	10.45	6.33
Net Income	-$65.78M	-$22.78M	$3.48B	$358.24M
7 Day Performance	8.83%	-1.22%	0.88%	1.17%
1 Month Performance	55.93%	-4.44%	-1.59%	-2.59%
1 Year Performance	-21.65%	37.78%	18.08%	5.97%

Arcturus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARCT Arcturus Therapeutics	2.9689 of 5 stars	$16.03 -5.3%	$23.00 +43.5%	-18.3%	$481.20M	$18.72M	N/A	111	News Coverage
NTLA Intellia Therapeutics	2.6804 of 5 stars	$11.87 +1.1%	$20.98 +76.7%	-24.6%	$1.65B	$67.67M	N/A	377
TSHA Taysha Gene Therapies	3.1761 of 5 stars	$5.01 -0.2%	$12.77 +154.9%	+67.9%	$1.64B	$5.49M	N/A	99	News Coverage Analyst Forecast High Trading Volume
FBRX Forte Biosciences	0.97 of 5 stars	$76.99 flat	$71.67 -6.9%	N/A	$1.63B	N/A	N/A	5
SNDX Syndax Pharmaceuticals	3.465 of 5 stars	$18.35 +0.9%	$42.30 +130.5%	+14.0%	$1.61B	$172.35M	N/A	298	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARCT) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. NTLA, TSHA, FBRX, SNDX, and INBX

How does Arcturus Therapeutics compare to Intellia Therapeutics?

Summary

How does Arcturus Therapeutics compare to Taysha Gene Therapies?

Summary

How does Arcturus Therapeutics compare to Forte Biosciences?

Summary

How does Arcturus Therapeutics compare to Syndax Pharmaceuticals?

Summary

How does Arcturus Therapeutics compare to Inhibrx Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. NTLA, TSHA, FBRX, SNDX, and INBX

How does Arcturus Therapeutics compare to Intellia Therapeutics?

Is NTLA or ARCT more profitable?

Do institutionals & insiders hold more shares of NTLA or ARCT?

Does the media refer more to NTLA or ARCT?

Do analysts recommend NTLA or ARCT?

Which has stronger valuation and earnings, NTLA or ARCT?

Which has more risk and volatility, NTLA or ARCT?

Summary

How does Arcturus Therapeutics compare to Taysha Gene Therapies?

Is TSHA or ARCT more profitable?

Does the media prefer TSHA or ARCT?

Do analysts recommend TSHA or ARCT?

Which has preferable earnings & valuation, TSHA or ARCT?

Which has more risk and volatility, TSHA or ARCT?

Do institutionals & insiders believe in TSHA or ARCT?

Summary

How does Arcturus Therapeutics compare to Forte Biosciences?

Does the media favor ARCT or FBRX?

Do analysts rate ARCT or FBRX?

Do institutionals and insiders hold more shares of ARCT or FBRX?

Which has higher earnings and valuation, ARCT or FBRX?

Is ARCT or FBRX more profitable?

Which has more risk and volatility, ARCT or FBRX?

Summary

How does Arcturus Therapeutics compare to Syndax Pharmaceuticals?

Does the media prefer SNDX or ARCT?

Do institutionals & insiders have more ownership in SNDX or ARCT?

Which has more volatility and risk, SNDX or ARCT?

Which has better valuation and earnings, SNDX or ARCT?

Is SNDX or ARCT more profitable?

Do analysts rate SNDX or ARCT?

Summary

How does Arcturus Therapeutics compare to Inhibrx Biosciences?

Does the media prefer ARCT or INBX?

Which has more volatility & risk, ARCT or INBX?

Which has preferable earnings and valuation, ARCT or INBX?

Do insiders and institutionals believe in ARCT or INBX?

Do analysts rate ARCT or INBX?

Is ARCT or INBX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools